This second installment of our six-part series—authored by Hinesh Patel, MCMI ChMC of CNM LLP, Chris Raphaely of Cozen O’Connor, Nathan Cali of NOBLE Capital Markets, and Matt Podowitz of Pathfinder Advisors—explores the concrete strategic opportunities for European companies in the U.S. middle-market health care and life sciences (HCLS) sector. European acquirers can unlock substantial value by accessing the U.S.’s deep and commercially mature market, tapping into leading biotech and biopharma innovation hubs, leveraging advanced digital and AI integration, and gaining immediate access to diverse patient populations for clinical research. Established U.S. commercial infrastructure and regulatory frameworks further support accelerated growth and market penetration.

Recent transactions, including Novo Holdings’ acquisition of Catalent and Alcon’s acquisition of Lensar, illustrate how European firms are strategically combining innovation, clinical access, and commercialization to drive transformative growth. By acquiring U.S. assets, European investors can accelerate scientific advancements, enhance operational capabilities, and capture significant competitive advantage. This strategic moment offers a compelling opportunity for transatlantic collaboration, delivering long-term value in a rapidly evolving HCLS landscape.

To read more, click here.